https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Immunotherapy 2014;6(3):349-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Immunotherapy 2014;6(3):349-602014-01-01 00:00:002019-02-15 08:50:00Dendritic cell-based vaccines: clinical applications in breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3132-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3132-82014-01-01 00:00:002021-12-15 16:11:43Novel dendritic cell-based vaccination in late stage melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-72014-01-01 00:00:002024-03-18 11:00:32Dendritic cell immunotherapy in uterine cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3125-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3125-312014-01-01 00:00:002019-02-15 08:32:45Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / CNS Oncol 2014;3(5):337-48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / CNS Oncol 2014;3(5):337-482014-01-01 00:00:002019-02-15 08:32:55Diffuse intrinsic pontine glioma: time for therapeutic optimism
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3261-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3261-92014-01-01 00:00:002019-02-15 08:39:33Tumor cell lysates as immunogenic sources for cancer vaccine design
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Methods Mol. Biol. 2014;1139:33-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Methods Mol. Biol. 2014;1139:33-402014-01-01 00:00:002019-02-15 08:39:43Antigen trapping by dendritic cells for antitumor therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Methods Mol. Biol. 2014;1139:17-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Methods Mol. Biol. 2014;1139:17-262014-01-01 00:00:002019-02-15 08:39:43Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-12-13 / Front Immunol 2013 Dec;4:454
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-12-13 / Front Immunol 2013 Dec;4:4542013-12-13 00:00:002019-02-15 08:39:46Dendritic cells in cancer immunotherapy clinical trials: are we making progress?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-12-03 / Front Immunol 2013 Dec;4:417
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-12-03 / Front Immunol 2013 Dec;4:4172013-12-03 00:00:002019-02-15 08:36:00Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
